Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Status:
Completed
Trial end date:
2018-04-19
Target enrollment:
Participant gender:
Summary
The primary objective was to estimate the proportion of participants with detectable
talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after
administration of talimogene laherparepvec within the first 3 cycles.